How much does a box of Adagraxibu cost?

Adagrasib is a new oral drug classified as a KRAS G12C inhibitor. It is designed to treat some specific types of cancer, especially advanced solid tumors associated with KRAS G12C mutations, including non-small cell lung cancer (NSCLC).

Since adagrasib is not yet available in the country, patients are currently unable to purchase it directly domestically and must resort to overseas channels. However, the original drug of adagrasib abroad, mainly from the United States, is extremely expensive, reaching more than 180,000 yuan, which is undoubtedly a heavy burden for ordinary families.

But what is gratifying is that foreign generic drugs have recently come out. Among them, the generic drug of adagrasibu produced by Lucius in Laos has attracted much attention. Its price is relatively affordable, only about four to five thousand yuan per box. More importantly, after comparison, it was found that the ingredients of this generic drug are basically the same as the original drug, providing patients with a more economical and affordable choice.

KRAS G12Cis a common cancer mutation, particularly inNSCLC, where it is found in a proportion of patients. This mutation leads to abnormal activation of the RAS pathway, which in turn promotes the proliferation and growth of cancer cells. The mechanism of action of adagrasib is to target the KRAS G12C mutation and inhibit the abnormal activation of the RAS pathway, thus blocking the growth and spread of tumor cells.

Compared with traditional chemotherapy drugs, adagrasib is a targeted drug with a more specific mechanism of action. It can intervene in abnormal signaling pathways in tumor cells more accurately, thereby reducing the adverse effects on normal cells and reducing the toxic side effects of patients.

Although adagrasib is currently in clinical trials, it has shown promise in treating KRAS G12C mutation-associated cancers. As further research and clinical trials proceed, people's understanding of adagrasib will continue to deepen, providing more personalized and effective treatment options for tumor patients.